| Title |
Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
|
|---|---|
| Published in |
Drug Design, Development and Therapy, August 2014
|
| DOI | 10.2147/dddt.s66812 |
| Pubmed ID | |
| Authors |
Junko H Ohyashiki, Kazushige Ohtsuki, Izuru Mizoguchi, Takayuki Yoshimoto, Seiichiro Katagiri, Tomohiro Umezu, Kazuma Ohyashiki |
| Abstract |
A subset of patients with chronic myeloid leukemia (CML) can sustain a complete molecular response after discontinuing imatinib mesylate (IM). We focused on microRNAs (miRNAs), with the aim of finding a molecular biomarker to discriminate which patients can safely and successfully discontinue IM use. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 18% |
| Student > Ph. D. Student | 5 | 15% |
| Student > Master | 5 | 15% |
| Student > Doctoral Student | 4 | 12% |
| Student > Postgraduate | 3 | 9% |
| Other | 7 | 21% |
| Unknown | 4 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 29% |
| Agricultural and Biological Sciences | 8 | 24% |
| Biochemistry, Genetics and Molecular Biology | 6 | 18% |
| Design | 2 | 6% |
| Engineering | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 3 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2014.
All research outputs
#23,214,800
of 25,870,940 outputs
Outputs from Drug Design, Development and Therapy
#1,769
of 2,287 outputs
Outputs of similar age
#207,454
of 241,265 outputs
Outputs of similar age from Drug Design, Development and Therapy
#31
of 38 outputs
Altmetric has tracked 25,870,940 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,287 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,265 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.